The memory of the ImClone Systems scandal, in which former chief executive Samuel Waksal is alleged to have tipped off celebrity Martha Stewart and his family members before telling the market of an FDA delay, is still fresh in many investors' minds.
Ever since a scandal over regulatory troubles and insider trading crushed ImClone's stock price six years ago, Wall Street analysts have speculated that Bristol might buy ImClone outright.